Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
AURA · Why this verdict
Why Aura Biosciences (AURA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Aura Biosciences' quality score of 1.7 sits below the engine's 4.0 floor, reflecting ongoing cash burn and no identified competitive moat. Quality breakdown | Cash burn narrows and the quality score climbs back above the 4.0 floor as clinical programs progress. | →Stable |
| CounterClinical-stage ophthalmic-oncology biotechs routinely burn cash pre-commercialization, so a low quality score doesn't necessarily reflect the value of the underlying pipeline. | ||
The insider gate failed with insider selling at 4.898% of market cap, classified as EXTREME severity, reflecting $39.2 million in net insider sales. Insider | Insider selling activity moderates well below the extreme-severity threshold in coming quarters. | →Stable |
| CounterA single large insider sale, potentially a scheduled or estate-planning transaction, can dominate the 90-day window without reflecting a broad loss of conviction among all insiders. | ||
The engine's asymmetry model shows a 7.42 risk/reward ratio with 111.3% modeled upside, and analysts imply 143% upside per the sentiment notes. Sentiment breakdown | Price appreciates meaningfully toward the take-profit level over the next 12 months. | →Stable |
| CounterExtreme implied upside on a speculative, quality-below-floor biotech often reflects analyst targets tied to binary clinical trial outcomes rather than achievable near-term value. | ||
The stock is overbought at RSI 74 with rising OBV accumulation volume, trading above its 200-day moving average per the momentum notes. Momentum breakdown | The momentum score, currently 7.6, stays above the 5.5 gate threshold as the uptrend continues. | →Stable |
| CounterAn RSI of 74 combined with extreme insider selling and 291% implied volatility raises the odds of a sharp pullback rather than continued momentum. | ||
Implied volatility sits at an extreme 291%, among the highest readings in the risk model, reflecting the binary nature of the company's clinical catalysts. Risk breakdown | Implied volatility moderates from the current 291% level as clinical uncertainty resolves one way or the other. | →Stable |
| CounterExtreme volatility ahead of a binary clinical readout is often structurally persistent until the actual data event occurs, rather than something that gradually moderates. | ||
Aura Biosciences' quality score of 1.7 sits below the engine's 4.0 floor, reflecting ongoing cash burn and no identified competitive moat.
→StableQuality breakdown
- Expectation
- Cash burn narrows and the quality score climbs back above the 4.0 floor as clinical programs progress.
CounterClinical-stage ophthalmic-oncology biotechs routinely burn cash pre-commercialization, so a low quality score doesn't necessarily reflect the value of the underlying pipeline.
The insider gate failed with insider selling at 4.898% of market cap, classified as EXTREME severity, reflecting $39.2 million in net insider sales.
→StableInsider
- Expectation
- Insider selling activity moderates well below the extreme-severity threshold in coming quarters.
CounterA single large insider sale, potentially a scheduled or estate-planning transaction, can dominate the 90-day window without reflecting a broad loss of conviction among all insiders.
The engine's asymmetry model shows a 7.42 risk/reward ratio with 111.3% modeled upside, and analysts imply 143% upside per the sentiment notes.
→StableSentiment breakdown
- Expectation
- Price appreciates meaningfully toward the take-profit level over the next 12 months.
CounterExtreme implied upside on a speculative, quality-below-floor biotech often reflects analyst targets tied to binary clinical trial outcomes rather than achievable near-term value.
The stock is overbought at RSI 74 with rising OBV accumulation volume, trading above its 200-day moving average per the momentum notes.
→StableMomentum breakdown
- Expectation
- The momentum score, currently 7.6, stays above the 5.5 gate threshold as the uptrend continues.
CounterAn RSI of 74 combined with extreme insider selling and 291% implied volatility raises the odds of a sharp pullback rather than continued momentum.
Implied volatility sits at an extreme 291%, among the highest readings in the risk model, reflecting the binary nature of the company's clinical catalysts.
→StableRisk breakdown
- Expectation
- Implied volatility moderates from the current 291% level as clinical uncertainty resolves one way or the other.
CounterExtreme volatility ahead of a binary clinical readout is often structurally persistent until the actual data event occurs, rather than something that gradually moderates.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Aura Biosciences offers high modeled upside and strong momentum ahead of binary clinical catalysts, but a quality score below the engine's floor, extreme insider selling, and sky-high implied volatility mark it as a highly speculative position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.9 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 8.9 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 5.9 |
- ▸Overbought (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 143%
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Heavy insider selling — $39,209,718 (4.898% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.1 |
| growth rank | 5.0 |
Technical
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 6.2 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 9.4 |
- ▸High IV: 303%
Catalyst
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.6>=5.5
- ASYMMETRY:7.4>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- INSIDER:4.90%=EXTREME
Warning (0)
none
Reward-to-Risk
7.42
Upside
+111.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor. Failed gate signal: INSIDER:4.90%=EXTREME.
The strongest dimensions are Value at 9.0, Momentum at 7.6, and Sentiment at 6.6; the weakest are Quality at 1.7, Technical at 2.1, and Peer rank at 2.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 7.42 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Engine Floor
Trip ifQuality score rises above 4.0 from the current 1.7, matching or clearing the engine's floor.
- P2Extreme Insider Selling Gate Failed
Trip ifInsider selling falls below 1% of market cap over a 90-day window, down from the current 4.898%.
- P3High Modeled Upside
Trip ifAsymmetry ratio falls below 2.0, down from the current 7.42.
- P4Overbought Uptrend Momentum
Trip ifMomentum score falls below 5.5, down from the current 7.6, ending the uptrend.
- P5Extreme Implied Volatility
Trip ifImplied volatility falls below 150%, down from the current 291%.